Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial

Clinical Colorectal Cancer

Volumn 15, Issue 4, 2016, Pages 377-380

  Marchetti, Paolo ^a   Milano, Annalisa ^a   D'Antonio, Chiara ^a   Romiti, Adriana ^a   Falcone, Rosa ^a   Roberto, Michela ^a   Fais, Stefano ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Acidity; Low dose chemotherapy; Rabeprazole; Refractory disease; Salvage chemotherapy

Indexed keywords

CAPECITABINE; RABEPRAZOLE; ANTINEOPLASTIC AGENT; PROTON PUMP INHIBITOR;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; DRUG ACTIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; KAPLAN MEIER METHOD; MALE; METHODOLOGY; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, METRONOMIC; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RABEPRAZOLE; RESEARCH DESIGN; SALVAGE THERAPY;

EID: 84996956371     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.06.005     Document Type: Article

References (15)

1. 1 Fais, S., Venturi, G., Gatenby, B., Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev 33 (2014), 1095–1108.
2. 2 Fais, S., Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 267 (2010), 515–525.
3. 3 Luciani, F., Spada, M., De Milito, A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 96 (2004), 1702–1713.
4. 4 De Milito, A., Canese, R., Marino, M.L., et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 127 (2010), 207–219.
5. 5 Spugnini, E.P., Baldi, A., Buglioni, S., et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med, 9, 2011, 221.
6. 6 Marino, M.L., Fais, S., Djavaheri-Mergny, M., et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis, 1, 2010, e87.
7. 7 Dadabhai, A., Friedenberg, F.K., Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf 8 (2009), 119–126.
8. 8 Ferrari, S., Perut, F., Fagioli, F., et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. J Transl Med, 11, 2013, 268.
9. 9 Brana, I., Ocana, A., Chen, E.X., et al. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs 32 (2014), 1269–1277.
10. 10 Wang, B.Y., Zhang, J., Wang, J.L., et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res, 34, 2015, 85.
11. 11 Romiti, A., Cox, M.C., Sarcina, I., et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 72 (2013), 13–33.
12. 12 André, N., Carré, M., Pasquier, E., Metronomics: towards personalized chemotherapy?. Nat Rev Clin Oncol 11 (2014), 413–431.
13. 13 Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 2016 May 17. http://dx.doi.org/10.1038/nrclinonc.2016.64. [Epub ahead of print].
14. 14 Roberto, M., Romiti, A., Onesti, C.E., et al. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anticancer Drugs 27 (2016), 106–111.
15. 15 Romiti, A., Onesti, C.E., Roberto, M., et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol, 32, 2015, 54.